Accentia Biopharmaceuticals to Announce Top-Line SinuNase Phase 3 Clinical Trial Results Later Today
Monday March 24, 8:52 am ET
CEO Conference Call/Webcast Scheduled for 5:00 p.m. (EDT)
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI - News) announced that at shortly after 4:00 p.m. (EDT) this afternoon, the Company will report the results for the primary endpoint in its Fast Track pivotal Phase 3 clinical trial evaluating the Company’s intranasal, low-dose antifungal lavage product, SinuNase™ (topical amphotericin B 0.01% suspension) for the treatment of chronic sinusitis. The news announcement will be followed by a conference call / webcast scheduled for 5:00 p.m. (EDT) today, hosted by Accentia’s Chairman, CEO and Founder, Dr. Frank O’Donnell, Jr.
Anyone interested in participating on the conference call should dial 1-877-407-9205 if calling within the United States or 1-201-689-8054 if calling internationally. Participants should ask for “Accentia’s SinuNase Phase 3 Results” conference call. There will be a playback available until April 7, 2008. To listen to the playback, please call 1-877-660-6853 if calling within the United States or 1-201-612-7415 if calling internationally. Please use Account# 286 and Conference ID# 278582 for replay.
The call is also being webcast by Vcall and can be accessed at Accentia’s website at accentia.net and at investorcalendar.com. To access the webcast, you will need to have the Windows Media Player or Real Player on your desk top.
---------------
Things that crazy nutty biotech companies do. |
